Literature DB >> 23070563

A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington's disease: looking for biomarkers.

Jolanta Krzysztoń-Russjan1, Daniel Zielonka, Joanna Jackiewicz, Sylwia Kuśmirek, Irena Bubko, Aneta Klimberg, Jerzy T Marcinkowski, Elżbieta L Anuszewska.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder characterized by a progressive motor and cognitive decline and the development of psychiatric symptoms. The origin of molecular and biochemical disturbances in HD is a mutation in the HTT gene, which is autosomally dominantly inherited. The altered huntingtin protein is ubiquitously expressed in the CNS, as well as in peripheral tissues. In this study we measured the metabolism changes in gene transcription in blood of HD gene carriers (premanifest and manifest combined) versus 28 healthy controls. The comparison revealed statistically significant Global Pattern Recognition Fold Change (FC) for 6 mRNA transcripts, reflecting an increase of: MAOB (FC = 3.07; p = 0.0005) which encodes an outer mitochondrial membrane-bound enzyme called monoamine oxidase type B; TGM2 (FC = 1.8; p = 0.02) encoding a transglutaminase 2 that mediates cellular stress; SLC2A4 (FC = 1.64; p = 0.02) solute carrier family 2 (facilitated glucose transporter) member 4; branched chain ketoacid dehydrogenase kinase (BCKDK) (FC = 1.34; p = 0.02); decrease of LDHA (FC = -1.16; p = 0.03) lactate dehydrogenase A; and brain-derived neurotrophic factor (BDNF) (FC = -2,11; p = 0.03). These distinguished changes coincided with HD progress. The analyses of gene transcription levels in sub-cohorts confirmed these changes and also revealed 28 statistically significant FCs of gene transcripts involved in ATP production and BCAA metabolism.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070563     DOI: 10.1007/s10863-012-9479-3

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  42 in total

Review 1.  Huntington's disease.

Authors:  S Davies; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

2.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

3.  Validation of plasma branched chain amino acids as biomarkers in Huntington disease.

Authors:  Fanny Mochel; Sandra Benaich; Daniel Rabier; Alexandra Durr
Journal:  Arch Neurol       Date:  2011-02

4.  Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

Authors:  Julie St-Pierre; Stavit Drori; Marc Uldry; Jessica M Silvaggi; James Rhee; Sibylle Jäger; Christoph Handschin; Kangni Zheng; Jiandie Lin; Wenli Yang; David K Simon; Robert Bachoo; Bruce M Spiegelman
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

5.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

Review 6.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

7.  Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin.

Authors:  Tamara Milakovic; Gail V W Johnson
Journal:  J Biol Chem       Date:  2005-06-27       Impact factor: 5.157

Review 8.  Mechanisms responsible for regulation of branched-chain amino acid catabolism.

Authors:  Robert A Harris; Mandar Joshi; Nam Ho Jeoung
Journal:  Biochem Biophys Res Commun       Date:  2004-01-09       Impact factor: 3.575

9.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

Authors:  Alexander V Panov; Claire-Anne Gutekunst; Blair R Leavitt; Michael R Hayden; James R Burke; Warren J Strittmatter; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2002-08       Impact factor: 24.884

10.  A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length.

Authors:  D R Langbehn; R R Brinkman; D Falush; J S Paulsen; M R Hayden
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

View more
  12 in total

1.  Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.

Authors:  Wei-Na Cong; Wayne Chadwick; Rui Wang; Caitlin M Daimon; Huan Cai; Jennifer Amma; William H Wood; Kevin G Becker; Bronwen Martin; Stuart Maudsley
Journal:  J Biol Chem       Date:  2014-12-11       Impact factor: 5.157

2.  Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptors.

Authors:  Kozo Hamada; Akiko Terauchi; Kyoko Nakamura; Takayasu Higo; Nobuyuki Nukina; Nagisa Matsumoto; Chihiro Hisatsune; Takeshi Nakamura; Katsuhiko Mikoshiba
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-08       Impact factor: 11.205

Review 3.  What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.

Authors:  Lukasz Przybyl; Magdalena Wozna-Wysocka; Emilia Kozlowska; Agnieszka Fiszer
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

4.  A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.

Authors:  Xin Du; Terence Y C Pang; Anthony J Hannan
Journal:  Front Neurol       Date:  2013-07-09       Impact factor: 4.003

5.  Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington's Disease Patients.

Authors:  Ashley Gutierrez; Jody Corey-Bloom; Elizabeth A Thomas; Paula Desplats
Journal:  Front Mol Neurosci       Date:  2020-01-23       Impact factor: 5.639

6.  Longitudinal expression changes are weak correlates of disease progression in Huntington's disease.

Authors:  Christopher T Mitchell; Irina Krier; Jamshid Arjomand; Beth Borowsky; Sarah J Tabrizi; Blair R Leavitt; Ruth Luthi-Carter
Journal:  Brain Commun       Date:  2020-10-17

7.  Small Non-coding RNAs Are Dysregulated in Huntington's Disease Transgenic Mice Independently of the Therapeutic Effects of an Environmental Intervention.

Authors:  Celine Dubois; Geraldine Kong; Harvey Tran; Shanshan Li; Terence Y Pang; Anthony J Hannan; Thibault Renoir
Journal:  Mol Neurobiol       Date:  2021-03-06       Impact factor: 5.590

8.  Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model.

Authors:  Marie Thérèse Besson; Karin Alegría; Pamela Garrido-Gerter; Luis Felipe Barros; Jean-Charles Liévens
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

9.  Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease.

Authors:  Federica Cesca; Elisa Bregant; Borut Peterlin; Maja Zadel; Giorgia Dubsky de Wittenau; Gabriele Siciliano; Roberto Ceravolo; Lucia Petrozzi; Giada Pauletto; Lorenzo Verriello; Paolo Bergonzi; Giuseppe Damante; Giovanni Barillari; Bruno Lucci; Francesco Curcio; Incoronata Renata Lonigro
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

10.  Proteomic characterization of secretory granules in dopaminergic neurons indicates chromogranin/secretogranin-mediated protein processing impairment in Parkinson's disease.

Authors:  Gehua Wen; Hao Pang; Xu Wu; Enzhu Jiang; Xique Zhang; Xiaoni Zhan
Journal:  Aging (Albany NY)       Date:  2021-08-21       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.